View Future GrowthMedi-Caps 과거 순이익 실적과거 기준 점검 0/6Medi-Caps 의 수입은 연평균 -74.3%의 비율로 감소해 온 반면, Packaging 산업은 연평균 12.2%의 비율로 증가했습니다. 매출은 연평균 29.4%의 비율로 감소해 왔습니다.핵심 정보-74.27%순이익 성장률-73.85%주당순이익(EPS) 성장률Packaging 산업 성장률19.13%매출 성장률-29.41%자기자본이익률-2.72%순이익률-24.40%최근 순이익 업데이트31 Mar 2026최근 과거 실적 업데이트Reported Earnings • May 23Full year 2026 earnings released: ₹2.44 loss per share (vs ₹0.46 loss in FY 2025)Full year 2026 results: ₹2.44 loss per share (further deteriorated from ₹0.46 loss in FY 2025). Revenue: ₹206.6m (down 19% from FY 2025). Net loss: ₹30.4m (loss widened 432% from FY 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 56 percentage points per year, which is a significant difference in performance.공고 • May 14Medi-Caps Limited to Report Q4, 2026 Results on May 21, 2026Medi-Caps Limited announced that they will report Q4, 2026 results on May 21, 2026Reported Earnings • Feb 12Third quarter 2026 earnings released: ₹0.61 loss per share (vs ₹1.64 loss in 3Q 2025)Third quarter 2026 results: ₹0.61 loss per share (improved from ₹1.64 loss in 3Q 2025). Revenue: ₹50.6m (up 26% from 3Q 2025). Net loss: ₹7.66m (loss narrowed 63% from 3Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 74 percentage points per year, which is a significant difference in performance.공고 • Feb 04Medi-Caps Limited to Report Q3, 2026 Results on Feb 11, 2026Medi-Caps Limited announced that they will report Q3, 2026 results at 12:15 PM, Indian Standard Time on Feb 11, 2026Reported Earnings • Nov 14Second quarter 2026 earnings released: ₹1.46 loss per share (vs ₹0.25 profit in 2Q 2025)Second quarter 2026 results: ₹1.46 loss per share (down from ₹0.25 profit in 2Q 2025). Revenue: ₹35.4m (down 57% from 2Q 2025). Net loss: ₹18.2m (down ₹21.3m from profit in 2Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 103 percentage points per year, which is a significant difference in performance.공고 • Nov 04Medi-Caps Limited to Report First Half, 2026 Results on Nov 12, 2025Medi-Caps Limited announced that they will report first half, 2026 results on Nov 12, 2025모든 업데이트 보기Recent updatesNew Risk • Jul 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.8% average weekly change). Earnings have declined by 74% per year over the past 5 years. Market cap is less than US$10m (₹331.6m market cap, or US$3.50m). Minor Risk Revenue is less than US$5m (₹124m revenue, or US$1.3m).Reported Earnings • May 23Full year 2026 earnings released: ₹2.44 loss per share (vs ₹0.46 loss in FY 2025)Full year 2026 results: ₹2.44 loss per share (further deteriorated from ₹0.46 loss in FY 2025). Revenue: ₹206.6m (down 19% from FY 2025). Net loss: ₹30.4m (loss widened 432% from FY 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 56 percentage points per year, which is a significant difference in performance.공고 • May 14Medi-Caps Limited to Report Q4, 2026 Results on May 21, 2026Medi-Caps Limited announced that they will report Q4, 2026 results on May 21, 2026New Risk • May 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 71% per year over the past 5 years. Market cap is less than US$10m (₹403.5m market cap, or US$4.24m). Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Revenue is less than US$5m (₹160m revenue, or US$1.7m).New Risk • Mar 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 71% per year over the past 5 years. Market cap is less than US$10m (₹313.1m market cap, or US$3.38m). Minor Risks Share price has been volatile over the past 3 months (7.6% average weekly change). Revenue is less than US$5m (₹160m revenue, or US$1.7m).Reported Earnings • Feb 12Third quarter 2026 earnings released: ₹0.61 loss per share (vs ₹1.64 loss in 3Q 2025)Third quarter 2026 results: ₹0.61 loss per share (improved from ₹1.64 loss in 3Q 2025). Revenue: ₹50.6m (up 26% from 3Q 2025). Net loss: ₹7.66m (loss narrowed 63% from 3Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 74 percentage points per year, which is a significant difference in performance.공고 • Feb 04Medi-Caps Limited to Report Q3, 2026 Results on Feb 11, 2026Medi-Caps Limited announced that they will report Q3, 2026 results at 12:15 PM, Indian Standard Time on Feb 11, 2026Reported Earnings • Nov 14Second quarter 2026 earnings released: ₹1.46 loss per share (vs ₹0.25 profit in 2Q 2025)Second quarter 2026 results: ₹1.46 loss per share (down from ₹0.25 profit in 2Q 2025). Revenue: ₹35.4m (down 57% from 2Q 2025). Net loss: ₹18.2m (down ₹21.3m from profit in 2Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 103 percentage points per year, which is a significant difference in performance.공고 • Nov 04Medi-Caps Limited to Report First Half, 2026 Results on Nov 12, 2025Medi-Caps Limited announced that they will report first half, 2026 results on Nov 12, 2025Reported Earnings • Aug 06First quarter 2026 earnings released: ₹2.80 loss per share (vs ₹0.45 loss in 1Q 2025)First quarter 2026 results: ₹2.80 loss per share (further deteriorated from ₹0.45 loss in 1Q 2025). Revenue: ₹30.2m (down 51% from 1Q 2025). Net loss: ₹34.9m (loss widened ₹29.4m from 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 113 percentage points per year, which is a significant difference in performance.공고 • Aug 05Medi-Caps Limited, Annual General Meeting, Sep 18, 2025Medi-Caps Limited, Annual General Meeting, Sep 18, 2025, at 12:30 Indian Standard Time.공고 • Jul 28Medi-Caps Limited to Report Q1, 2026 Results on Aug 05, 2025Medi-Caps Limited announced that they will report Q1, 2026 results on Aug 05, 2025Reported Earnings • May 22Full year 2025 earnings released: ₹0.46 loss per share (vs ₹1.80 loss in FY 2024)Full year 2025 results: ₹0.46 loss per share (improved from ₹1.80 loss in FY 2024). Revenue: ₹282.1m (up 3.2% from FY 2024). Net loss: ₹5.71m (loss narrowed 75% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 116 percentage points per year, which is a significant difference in performance.공고 • May 14Medi-Caps Limited to Report Q4, 2025 Results on May 21, 2025Medi-Caps Limited announced that they will report Q4, 2025 results at 12:15 PM, Indian Standard Time on May 21, 2025New Risk • Feb 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 19% per year over the past 5 years. Market cap is less than US$10m (₹589.6m market cap, or US$6.76m). Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Revenue is less than US$5m (₹264m revenue, or US$3.0m).공고 • Feb 03Medi-Caps Limited to Report Q3, 2025 Results on Feb 12, 2025Medi-Caps Limited announced that they will report Q3, 2025 results at 12:15 PM, Indian Standard Time on Feb 12, 2025New Risk • Jan 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 12% per year over the past 5 years. Market cap is less than US$10m (₹722.0m market cap, or US$8.41m). Minor Risks Share price has been volatile over the past 3 months (8.2% average weekly change). Revenue is less than US$5m (₹294m revenue, or US$3.4m).Reported Earnings • Nov 13Second quarter 2025 earnings released: EPS: ₹0.25 (vs ₹0.09 in 2Q 2024)Second quarter 2025 results: EPS: ₹0.25 (up from ₹0.09 in 2Q 2024). Revenue: ₹85.8m (up 42% from 2Q 2024). Net income: ₹3.12m (up 170% from 2Q 2024). Profit margin: 3.6% (up from 1.9% in 2Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 119 percentage points per year, which is a significant difference in performance.공고 • Nov 09Medi-Caps Limited to Report Q2, 2025 Results on Nov 12, 2024Medi-Caps Limited announced that they will report Q2, 2025 results on Nov 12, 2024Reported Earnings • Aug 08First quarter 2025 earnings released: ₹0.45 loss per share (vs ₹0.89 loss in 1Q 2024)First quarter 2025 results: ₹0.45 loss per share (improved from ₹0.89 loss in 1Q 2024). Revenue: ₹63.4m (flat on 1Q 2024). Net loss: ₹5.57m (loss narrowed 50% from 1Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 105 percentage points per year, which is a significant difference in performance.공고 • Aug 07Medi-Caps Limited, Annual General Meeting, Sep 26, 2024Medi-Caps Limited, Annual General Meeting, Sep 26, 2024, at 12:30 Indian Standard Time.공고 • Aug 02Medi-Caps Limited to Report Q1, 2025 Results on Aug 07, 2024Medi-Caps Limited announced that they will report Q1, 2025 results on Aug 07, 2024공고 • May 30Medi-Caps Limited Announces Retirement of Mr. Pramod Fatehpuria as Independent DirectorMedi-Caps Limited informed that Mr. Pramod Fatehpuria (DIN: 00972389) will complete his second and final term as an Independent Director of the Company pursuant to the provisions of Sub-Section 11 of Section 149 of the Companies Act, 2013 with effect from the close of business hours on 28 May, 2024. Consequently, he will retire from Independent Directorship of the Company.Reported Earnings • May 25Full year 2024 earnings released: ₹1.80 loss per share (vs ₹1.50 profit in FY 2023)Full year 2024 results: ₹1.80 loss per share (down from ₹1.50 profit in FY 2023). Revenue: ₹278.2m (down 44% from FY 2023). Net loss: ₹22.4m (down 220% from profit in FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 93 percentage points per year, which is a significant difference in performance.공고 • May 17Medi-Caps Limited to Report Q4, 2024 Results on May 23, 2024Medi-Caps Limited announced that they will report Q4, 2024 results on May 23, 2024Board Change • Mar 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 2 experienced directors. 4 highly experienced directors. Non-Executive Independent Director Gajendra Singh was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Feb 09Third quarter 2024 earnings released: ₹0.13 loss per share (vs ₹1.04 loss in 3Q 2023)Third quarter 2024 results: ₹0.13 loss per share (improved from ₹1.04 loss in 3Q 2023). Revenue: ₹71.6m (down 35% from 3Q 2023). Net loss: ₹1.64m (loss narrowed 87% from 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 90 percentage points per year, which is a significant difference in performance.Reported Earnings • Nov 14Second quarter 2024 earnings released: EPS: ₹0.09 (vs ₹1.74 in 2Q 2023)Second quarter 2024 results: EPS: ₹0.09 (down from ₹1.74 in 2Q 2023). Revenue: ₹60.3m (down 61% from 2Q 2023). Net income: ₹1.16m (down 95% from 2Q 2023). Profit margin: 1.9% (down from 14% in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has increased by 33% per year, which means it is well ahead of earnings.New Risk • Nov 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹631.6m market cap, or US$7.58m). Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Profit margins are more than 30% lower than last year (0.3% net profit margin).공고 • Nov 09Medi-Caps Limited Announces Change in ManagementMedi-Caps Limited announced the appointment of Mr. Akshit Garg as General Manager under the category of Senior Management Personnel. Date of Appointment: 08th November, 2023. Age 29 years. Education/Qualification:-Masters in Management and Finance from Royal Melbourne Institute of Technology, Australia. He is young and energetic having more than 5 years of experience in the field of marketing and in charge of overall business growth. He possesses great leadership and management skills and has Ability to delegate tasks, supervise others and provides utmost attention to details. He has strong interpersonal skills and a great Technological acumen. The company also announced the appointment of Mrs. Saloni Garg as Senior Manager under the category of Senior Management Personnel. Date of Appointment: 08th November, 2023. Age 28 years. Education/Qualification:- Graduate in Business Management from Mumbai Masters in Brand Management from Italy. Past experience as a Freelance Brand Manager and helping businesses find their identity, brand logos, websites, communication design and also having vast experience of day to day workings of an organization to ensure efficient performance.공고 • Oct 01Medi-Caps Limited Approves Change in Designation of Gajendra Singh from Additional Director to Non Executive Independent DirectorMedi-Caps Limited at its AGM held on September 29, 2023 approved Change in designation of Mr. Gajendra Singh (DIN: 10253991) from Additional Director to Non Executive Independent Director. Age is 38 years. Education/Qualification is B.Com, Masters of Social work (MSW). Experience: He Possess vast experience and good exposure in strategic Management and Administration. He is well versed with optimum utilization of resources.공고 • Aug 30Medi-Caps Limited, Annual General Meeting, Sep 29, 2023Medi-Caps Limited, Annual General Meeting, Sep 29, 2023, at 12:30 Indian Standard Time.공고 • Aug 12Medi-Caps Limited Appoints Gajendra Singh as an Additional DirectorMedi-Caps Limited announced the appointment of Mr. Gajendra Singh as an Additional Director under the category of Non Executive Independent Director. Date of Appointment is 11th August, 2023. He Possess vast experience and good exposure in strategic Management and Administration. He is well versed with optimum utilization of resources.공고 • Aug 05Medi-Caps Limited to Report Q1, 2024 Results on Aug 11, 2023Medi-Caps Limited announced that they will report Q1, 2024 results on Aug 11, 2023공고 • Jul 14Medi-Caps Limited Announces Resignation of Akshit Garg as Non Executive Non Independent DirectorMedi-Caps Limited announced that Mr. Akshit Garg has received letter dated 13th July, 2023 resigned from the position of "Non Executive Non Independent Director" of the Company with effect from 21st July, 2023.Reported Earnings • May 25Full year 2023 earnings released: EPS: ₹1.50 (vs ₹8.05 in FY 2022)Full year 2023 results: EPS: ₹1.50 (down from ₹8.05 in FY 2022). Revenue: ₹509.7m (down 27% from FY 2022). Net income: ₹18.6m (down 81% from FY 2022). Profit margin: 3.7% (down from 14% in FY 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has increased by 55% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Apr 05Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹37.33, the stock trades at a trailing P/E ratio of 15.8x. Average trailing P/E is 15x in the Packaging industry in India. Total returns to shareholders of 293% over the past three years.Reported Earnings • Feb 12Third quarter 2023 earnings released: ₹1.04 loss per share (vs ₹1.67 profit in 3Q 2022)Third quarter 2023 results: ₹1.04 loss per share (down from ₹1.67 profit in 3Q 2022). Revenue: ₹110.4m (down 38% from 3Q 2022). Net loss: ₹13.0m (down 162% from profit in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has increased by 63% per year, which means it is tracking significantly ahead of earnings growth.공고 • Feb 02Medi-Caps Limited to Report Q3, 2023 Results on Feb 09, 2023Medi-Caps Limited announced that they will report Q3, 2023 results on Feb 09, 2023공고 • Nov 05Medi-Caps Limited to Report Q2, 2023 Results on Nov 10, 2022Medi-Caps Limited announced that they will report Q2, 2023 results on Nov 10, 2022Valuation Update With 7 Day Price Move • Aug 11Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₹44.30, the stock trades at a trailing P/E ratio of 7.5x. Average trailing P/E is 13x in the Packaging industry in India. Total returns to shareholders of 158% over the past three years.공고 • Aug 06Medi-Caps Limited, Annual General Meeting, Sep 28, 2022Medi-Caps Limited, Annual General Meeting, Sep 28, 2022, at 12:00 Indian Standard Time.Reported Earnings • Aug 05First quarter 2023 earnings released: EPS: ₹0.52 (vs ₹2.63 in 1Q 2022)First quarter 2023 results: EPS: ₹0.52 (down from ₹2.63 in 1Q 2022). Revenue: ₹126.9m (down 27% from 1Q 2022). Net income: ₹6.32m (down 81% from 1Q 2022). Profit margin: 5.0% (down from 19% in 1Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has only increased by 39% per year, which means it is significantly lagging earnings growth.공고 • Jul 28Medi-Caps Limited to Report Q1, 2023 Results on Aug 04, 2022Medi-Caps Limited announced that they will report Q1, 2023 results on Aug 04, 2022Valuation Update With 7 Day Price Move • Jun 17Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₹43.20, the stock trades at a trailing P/E ratio of 5.4x. Average trailing P/E is 15x in the Packaging industry in India. Total returns to shareholders of 122% over the past three years.Reported Earnings • May 30Full year 2022 earnings released: EPS: ₹8.05 (vs ₹9.02 in FY 2021)Full year 2022 results: EPS: ₹8.05 (down from ₹9.02 in FY 2021). Revenue: ₹698.7m (up 20% from FY 2021). Net income: ₹100.4m (down 11% from FY 2021). Profit margin: 14% (down from 19% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has only increased by 48% per year, which means it is significantly lagging earnings growth.공고 • May 18Medi-Caps Limited to Report Q4, 2022 Results on May 25, 2022Medi-Caps Limited announced that they will report Q4, 2022 results on May 25, 2022Valuation Update With 7 Day Price Move • Apr 06Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹57.00, the stock trades at a trailing P/E ratio of 6.5x. Average trailing P/E is 14x in the Packaging industry in India. Total returns to shareholders of 279% over the past three years.Valuation Update With 7 Day Price Move • Feb 22Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₹50.55, the stock trades at a trailing P/E ratio of 5.8x. Average trailing P/E is 14x in the Packaging industry in India. Total returns to shareholders of 288% over the past three years.Valuation Update With 7 Day Price Move • Feb 22Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₹50.55, the stock trades at a trailing P/E ratio of 5.8x. Average trailing P/E is 14x in the Packaging industry in India. Total returns to shareholders of 288% over the past three years.Reported Earnings • Feb 13Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹1.67 (down from ₹2.75 in 3Q 2021). Revenue: ₹180.0m (down 1.5% from 3Q 2021). Net income: ₹20.8m (down 39% from 3Q 2021). Profit margin: 12% (down from 19% in 3Q 2021). The decrease in margin was primarily driven by higher expenses. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 68% per year whereas the company’s share price has increased by 67% per year.공고 • Feb 03Medi-Caps Limited to Report Q3, 2022 Results on Feb 10, 2022Medi-Caps Limited announced that they will report Q3, 2022 results on Feb 10, 2022Reported Earnings • Nov 12Second quarter 2022 earnings released: EPS ₹2.59 (vs ₹2.94 in 2Q 2021)The company reported a solid second quarter result with improved earnings and revenues, although profit margins were weaker. Second quarter 2022 results: Revenue: ₹174.4m (up 17% from 2Q 2021). Net income: ₹32.3m (up 3.3% from 2Q 2021). Profit margin: 19% (down from 21% in 2Q 2021). The decrease in margin was driven by higher expenses.Reported Earnings • Jun 29Full year 2021 earnings released: EPS ₹11.16 (vs ₹4.69 loss in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹593.0m (up 33% from FY 2020). Net income: ₹112.4m (up ₹171.0m from FY 2020). Profit margin: 19% (up from net loss in FY 2020). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has only increased by 34% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • May 25Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹49.40, the stock trades at a trailing P/E ratio of 4.3x. Average trailing P/E is 14x in the Packaging industry in India. Total returns to shareholders of 134% over the past three years.Valuation Update With 7 Day Price Move • Mar 06Investor sentiment improved over the past weekAfter last week's 19% share price gain to ₹35.00, the stock is trading at a trailing P/E ratio of 3x, up from the previous P/E ratio of 2.5x. This compares to an average P/E of 10x in the Packaging industry in India. Total returns to shareholders over the past three years are 51%.Is New 90 Day High Low • Mar 05New 90-day high: ₹35.00The company is up 54% from its price of ₹22.75 on 04 December 2020. The Indian market is up 17% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Packaging industry, which is up 4.0% over the same period.Valuation Update With 7 Day Price Move • Feb 12Investor sentiment improved over the past weekAfter last week's 42% share price gain to ₹34.80, the stock is trading at a trailing P/E ratio of 3x, up from the previous P/E ratio of 2.1x. This compares to an average P/E of 10x in the Packaging industry in India. Total returns to shareholders over the past three years are 35%.Is New 90 Day High Low • Feb 08New 90-day high: ₹29.45The company is up 33% from its price of ₹22.10 on 10 November 2020. The Indian market is up 21% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Packaging industry, which is up 5.0% over the same period.공고 • Feb 06Medi-Caps Limited Appoints Dharmendra Solanki as an Additional as Well as Non Executive Independent DirectorMedi-Caps Limited at its board meeting held on February 5, 2021 approved the appointment of Dharmendra Solanki as an additional as well as non executive independent Director in the company.Reported Earnings • Feb 06Third quarter 2021 earnings released: EPS ₹3.54 (vs ₹2.63 loss in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₹182.7m (up 114% from 3Q 2020). Net income: ₹34.3m (up ₹67.5m from 3Q 2020). Profit margin: 19% (up from net loss in 3Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.공고 • Feb 01Medi-Caps Limited to Report Q3, 2021 Results on Feb 05, 2021Medi-Caps Limited announced that they will report Q3, 2021 results on Feb 05, 2021Is New 90 Day High Low • Dec 09New 90-day high: ₹24.65The company is up 23% from its price of ₹20.05 on 10 September 2020. The Indian market is up 19% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Packaging industry, which is up 10.0% over the same period.공고 • Nov 25Medi-Caps Limited Announces Demise of Shamsher Singh, Non-Executive Independent DirectorMedi-Caps Limited announced sudden and sad demise of Mr. Shamsher Singh, Non-Executive Independent Director of the Company, on 20 November, 2020. Mr. Shamsher Singh was on the Board of the Company since April 30, 2002 and the Company immensely benefitted from his vision and contribution during his tenure.Is New 90 Day High Low • Nov 12New 90-day high: ₹23.95The company is up 9.0% from its price of ₹21.90 on 14 August 2020. The Indian market is also up 9.0% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Packaging industry, which is down 2.0% over the same period.공고 • Oct 30Medi-Caps Limited to Report Q2, 2021 Results on Nov 06, 2020Medi-Caps Limited announced that they will report Q2, 2021 results on Nov 06, 2020공고 • Jun 21Medi-Caps Limited to Report Q4, 2020 Results on Jun 26, 2020Medi-Caps Limited announced that they will report Q4, 2020 results on Jun 26, 2020매출 및 비용 세부 내역Medi-Caps가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이BSE:523144 매출, 비용 및 순이익 (INR Millions)날짜매출순이익일반관리비연구개발비31 Mar 26124-3088031 Dec 25160-4481030 Sep 25157-5680030 Jun 25220-3591031 Mar 25255-682031 Dec 24264-3485030 Sep 24294-1586030 Jun 24272-1788031 Mar 24273-2278031 Dec 23300-850030 Sep 23340-1955030 Jun 234341113031 Mar 234941985031 Dec 225642967030 Sep 2263163103030 Jun 2265074200031 Mar 2269910092031 Dec 21655109139030 Sep 2165912280030 Jun 2163612170031 Mar 2158711275031 Dec 205288073030 Sep 204401398030 Jun 20422-41100031 Mar 20446-59114031 Dec 19506-24120030 Sep 1955128100030 Jun 195977897031 Mar 195305499031 Mar 185021192031 Mar 174401492031 Mar 164309830양질의 수익: 523144 은(는) 현재 수익성이 없습니다.이익 마진 증가: 523144는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 523144은 수익성이 없으며 지난 5년 동안 손실이 연평균 74.3% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 523144의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: 523144은 수익성이 없어 지난 해 수익 성장률을 Packaging 업계(8.5%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: 523144는 현재 수익성이 없으므로 자본 수익률이 음수(-2.72%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YMaterials 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/18 16:00종가2026/07/17 00:00수익2026/03/31연간 수익2026/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Medi-Caps Limited는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • May 23Full year 2026 earnings released: ₹2.44 loss per share (vs ₹0.46 loss in FY 2025)Full year 2026 results: ₹2.44 loss per share (further deteriorated from ₹0.46 loss in FY 2025). Revenue: ₹206.6m (down 19% from FY 2025). Net loss: ₹30.4m (loss widened 432% from FY 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 56 percentage points per year, which is a significant difference in performance.
공고 • May 14Medi-Caps Limited to Report Q4, 2026 Results on May 21, 2026Medi-Caps Limited announced that they will report Q4, 2026 results on May 21, 2026
Reported Earnings • Feb 12Third quarter 2026 earnings released: ₹0.61 loss per share (vs ₹1.64 loss in 3Q 2025)Third quarter 2026 results: ₹0.61 loss per share (improved from ₹1.64 loss in 3Q 2025). Revenue: ₹50.6m (up 26% from 3Q 2025). Net loss: ₹7.66m (loss narrowed 63% from 3Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 74 percentage points per year, which is a significant difference in performance.
공고 • Feb 04Medi-Caps Limited to Report Q3, 2026 Results on Feb 11, 2026Medi-Caps Limited announced that they will report Q3, 2026 results at 12:15 PM, Indian Standard Time on Feb 11, 2026
Reported Earnings • Nov 14Second quarter 2026 earnings released: ₹1.46 loss per share (vs ₹0.25 profit in 2Q 2025)Second quarter 2026 results: ₹1.46 loss per share (down from ₹0.25 profit in 2Q 2025). Revenue: ₹35.4m (down 57% from 2Q 2025). Net loss: ₹18.2m (down ₹21.3m from profit in 2Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 103 percentage points per year, which is a significant difference in performance.
공고 • Nov 04Medi-Caps Limited to Report First Half, 2026 Results on Nov 12, 2025Medi-Caps Limited announced that they will report first half, 2026 results on Nov 12, 2025
New Risk • Jul 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.8% average weekly change). Earnings have declined by 74% per year over the past 5 years. Market cap is less than US$10m (₹331.6m market cap, or US$3.50m). Minor Risk Revenue is less than US$5m (₹124m revenue, or US$1.3m).
Reported Earnings • May 23Full year 2026 earnings released: ₹2.44 loss per share (vs ₹0.46 loss in FY 2025)Full year 2026 results: ₹2.44 loss per share (further deteriorated from ₹0.46 loss in FY 2025). Revenue: ₹206.6m (down 19% from FY 2025). Net loss: ₹30.4m (loss widened 432% from FY 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 56 percentage points per year, which is a significant difference in performance.
공고 • May 14Medi-Caps Limited to Report Q4, 2026 Results on May 21, 2026Medi-Caps Limited announced that they will report Q4, 2026 results on May 21, 2026
New Risk • May 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 71% per year over the past 5 years. Market cap is less than US$10m (₹403.5m market cap, or US$4.24m). Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Revenue is less than US$5m (₹160m revenue, or US$1.7m).
New Risk • Mar 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 71% per year over the past 5 years. Market cap is less than US$10m (₹313.1m market cap, or US$3.38m). Minor Risks Share price has been volatile over the past 3 months (7.6% average weekly change). Revenue is less than US$5m (₹160m revenue, or US$1.7m).
Reported Earnings • Feb 12Third quarter 2026 earnings released: ₹0.61 loss per share (vs ₹1.64 loss in 3Q 2025)Third quarter 2026 results: ₹0.61 loss per share (improved from ₹1.64 loss in 3Q 2025). Revenue: ₹50.6m (up 26% from 3Q 2025). Net loss: ₹7.66m (loss narrowed 63% from 3Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 74 percentage points per year, which is a significant difference in performance.
공고 • Feb 04Medi-Caps Limited to Report Q3, 2026 Results on Feb 11, 2026Medi-Caps Limited announced that they will report Q3, 2026 results at 12:15 PM, Indian Standard Time on Feb 11, 2026
Reported Earnings • Nov 14Second quarter 2026 earnings released: ₹1.46 loss per share (vs ₹0.25 profit in 2Q 2025)Second quarter 2026 results: ₹1.46 loss per share (down from ₹0.25 profit in 2Q 2025). Revenue: ₹35.4m (down 57% from 2Q 2025). Net loss: ₹18.2m (down ₹21.3m from profit in 2Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 103 percentage points per year, which is a significant difference in performance.
공고 • Nov 04Medi-Caps Limited to Report First Half, 2026 Results on Nov 12, 2025Medi-Caps Limited announced that they will report first half, 2026 results on Nov 12, 2025
Reported Earnings • Aug 06First quarter 2026 earnings released: ₹2.80 loss per share (vs ₹0.45 loss in 1Q 2025)First quarter 2026 results: ₹2.80 loss per share (further deteriorated from ₹0.45 loss in 1Q 2025). Revenue: ₹30.2m (down 51% from 1Q 2025). Net loss: ₹34.9m (loss widened ₹29.4m from 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 113 percentage points per year, which is a significant difference in performance.
공고 • Aug 05Medi-Caps Limited, Annual General Meeting, Sep 18, 2025Medi-Caps Limited, Annual General Meeting, Sep 18, 2025, at 12:30 Indian Standard Time.
공고 • Jul 28Medi-Caps Limited to Report Q1, 2026 Results on Aug 05, 2025Medi-Caps Limited announced that they will report Q1, 2026 results on Aug 05, 2025
Reported Earnings • May 22Full year 2025 earnings released: ₹0.46 loss per share (vs ₹1.80 loss in FY 2024)Full year 2025 results: ₹0.46 loss per share (improved from ₹1.80 loss in FY 2024). Revenue: ₹282.1m (up 3.2% from FY 2024). Net loss: ₹5.71m (loss narrowed 75% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 116 percentage points per year, which is a significant difference in performance.
공고 • May 14Medi-Caps Limited to Report Q4, 2025 Results on May 21, 2025Medi-Caps Limited announced that they will report Q4, 2025 results at 12:15 PM, Indian Standard Time on May 21, 2025
New Risk • Feb 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 19% per year over the past 5 years. Market cap is less than US$10m (₹589.6m market cap, or US$6.76m). Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Revenue is less than US$5m (₹264m revenue, or US$3.0m).
공고 • Feb 03Medi-Caps Limited to Report Q3, 2025 Results on Feb 12, 2025Medi-Caps Limited announced that they will report Q3, 2025 results at 12:15 PM, Indian Standard Time on Feb 12, 2025
New Risk • Jan 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 12% per year over the past 5 years. Market cap is less than US$10m (₹722.0m market cap, or US$8.41m). Minor Risks Share price has been volatile over the past 3 months (8.2% average weekly change). Revenue is less than US$5m (₹294m revenue, or US$3.4m).
Reported Earnings • Nov 13Second quarter 2025 earnings released: EPS: ₹0.25 (vs ₹0.09 in 2Q 2024)Second quarter 2025 results: EPS: ₹0.25 (up from ₹0.09 in 2Q 2024). Revenue: ₹85.8m (up 42% from 2Q 2024). Net income: ₹3.12m (up 170% from 2Q 2024). Profit margin: 3.6% (up from 1.9% in 2Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 119 percentage points per year, which is a significant difference in performance.
공고 • Nov 09Medi-Caps Limited to Report Q2, 2025 Results on Nov 12, 2024Medi-Caps Limited announced that they will report Q2, 2025 results on Nov 12, 2024
Reported Earnings • Aug 08First quarter 2025 earnings released: ₹0.45 loss per share (vs ₹0.89 loss in 1Q 2024)First quarter 2025 results: ₹0.45 loss per share (improved from ₹0.89 loss in 1Q 2024). Revenue: ₹63.4m (flat on 1Q 2024). Net loss: ₹5.57m (loss narrowed 50% from 1Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 105 percentage points per year, which is a significant difference in performance.
공고 • Aug 07Medi-Caps Limited, Annual General Meeting, Sep 26, 2024Medi-Caps Limited, Annual General Meeting, Sep 26, 2024, at 12:30 Indian Standard Time.
공고 • Aug 02Medi-Caps Limited to Report Q1, 2025 Results on Aug 07, 2024Medi-Caps Limited announced that they will report Q1, 2025 results on Aug 07, 2024
공고 • May 30Medi-Caps Limited Announces Retirement of Mr. Pramod Fatehpuria as Independent DirectorMedi-Caps Limited informed that Mr. Pramod Fatehpuria (DIN: 00972389) will complete his second and final term as an Independent Director of the Company pursuant to the provisions of Sub-Section 11 of Section 149 of the Companies Act, 2013 with effect from the close of business hours on 28 May, 2024. Consequently, he will retire from Independent Directorship of the Company.
Reported Earnings • May 25Full year 2024 earnings released: ₹1.80 loss per share (vs ₹1.50 profit in FY 2023)Full year 2024 results: ₹1.80 loss per share (down from ₹1.50 profit in FY 2023). Revenue: ₹278.2m (down 44% from FY 2023). Net loss: ₹22.4m (down 220% from profit in FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 93 percentage points per year, which is a significant difference in performance.
공고 • May 17Medi-Caps Limited to Report Q4, 2024 Results on May 23, 2024Medi-Caps Limited announced that they will report Q4, 2024 results on May 23, 2024
Board Change • Mar 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 2 experienced directors. 4 highly experienced directors. Non-Executive Independent Director Gajendra Singh was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Feb 09Third quarter 2024 earnings released: ₹0.13 loss per share (vs ₹1.04 loss in 3Q 2023)Third quarter 2024 results: ₹0.13 loss per share (improved from ₹1.04 loss in 3Q 2023). Revenue: ₹71.6m (down 35% from 3Q 2023). Net loss: ₹1.64m (loss narrowed 87% from 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 90 percentage points per year, which is a significant difference in performance.
Reported Earnings • Nov 14Second quarter 2024 earnings released: EPS: ₹0.09 (vs ₹1.74 in 2Q 2023)Second quarter 2024 results: EPS: ₹0.09 (down from ₹1.74 in 2Q 2023). Revenue: ₹60.3m (down 61% from 2Q 2023). Net income: ₹1.16m (down 95% from 2Q 2023). Profit margin: 1.9% (down from 14% in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has increased by 33% per year, which means it is well ahead of earnings.
New Risk • Nov 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹631.6m market cap, or US$7.58m). Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Profit margins are more than 30% lower than last year (0.3% net profit margin).
공고 • Nov 09Medi-Caps Limited Announces Change in ManagementMedi-Caps Limited announced the appointment of Mr. Akshit Garg as General Manager under the category of Senior Management Personnel. Date of Appointment: 08th November, 2023. Age 29 years. Education/Qualification:-Masters in Management and Finance from Royal Melbourne Institute of Technology, Australia. He is young and energetic having more than 5 years of experience in the field of marketing and in charge of overall business growth. He possesses great leadership and management skills and has Ability to delegate tasks, supervise others and provides utmost attention to details. He has strong interpersonal skills and a great Technological acumen. The company also announced the appointment of Mrs. Saloni Garg as Senior Manager under the category of Senior Management Personnel. Date of Appointment: 08th November, 2023. Age 28 years. Education/Qualification:- Graduate in Business Management from Mumbai Masters in Brand Management from Italy. Past experience as a Freelance Brand Manager and helping businesses find their identity, brand logos, websites, communication design and also having vast experience of day to day workings of an organization to ensure efficient performance.
공고 • Oct 01Medi-Caps Limited Approves Change in Designation of Gajendra Singh from Additional Director to Non Executive Independent DirectorMedi-Caps Limited at its AGM held on September 29, 2023 approved Change in designation of Mr. Gajendra Singh (DIN: 10253991) from Additional Director to Non Executive Independent Director. Age is 38 years. Education/Qualification is B.Com, Masters of Social work (MSW). Experience: He Possess vast experience and good exposure in strategic Management and Administration. He is well versed with optimum utilization of resources.
공고 • Aug 30Medi-Caps Limited, Annual General Meeting, Sep 29, 2023Medi-Caps Limited, Annual General Meeting, Sep 29, 2023, at 12:30 Indian Standard Time.
공고 • Aug 12Medi-Caps Limited Appoints Gajendra Singh as an Additional DirectorMedi-Caps Limited announced the appointment of Mr. Gajendra Singh as an Additional Director under the category of Non Executive Independent Director. Date of Appointment is 11th August, 2023. He Possess vast experience and good exposure in strategic Management and Administration. He is well versed with optimum utilization of resources.
공고 • Aug 05Medi-Caps Limited to Report Q1, 2024 Results on Aug 11, 2023Medi-Caps Limited announced that they will report Q1, 2024 results on Aug 11, 2023
공고 • Jul 14Medi-Caps Limited Announces Resignation of Akshit Garg as Non Executive Non Independent DirectorMedi-Caps Limited announced that Mr. Akshit Garg has received letter dated 13th July, 2023 resigned from the position of "Non Executive Non Independent Director" of the Company with effect from 21st July, 2023.
Reported Earnings • May 25Full year 2023 earnings released: EPS: ₹1.50 (vs ₹8.05 in FY 2022)Full year 2023 results: EPS: ₹1.50 (down from ₹8.05 in FY 2022). Revenue: ₹509.7m (down 27% from FY 2022). Net income: ₹18.6m (down 81% from FY 2022). Profit margin: 3.7% (down from 14% in FY 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has increased by 55% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Apr 05Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹37.33, the stock trades at a trailing P/E ratio of 15.8x. Average trailing P/E is 15x in the Packaging industry in India. Total returns to shareholders of 293% over the past three years.
Reported Earnings • Feb 12Third quarter 2023 earnings released: ₹1.04 loss per share (vs ₹1.67 profit in 3Q 2022)Third quarter 2023 results: ₹1.04 loss per share (down from ₹1.67 profit in 3Q 2022). Revenue: ₹110.4m (down 38% from 3Q 2022). Net loss: ₹13.0m (down 162% from profit in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has increased by 63% per year, which means it is tracking significantly ahead of earnings growth.
공고 • Feb 02Medi-Caps Limited to Report Q3, 2023 Results on Feb 09, 2023Medi-Caps Limited announced that they will report Q3, 2023 results on Feb 09, 2023
공고 • Nov 05Medi-Caps Limited to Report Q2, 2023 Results on Nov 10, 2022Medi-Caps Limited announced that they will report Q2, 2023 results on Nov 10, 2022
Valuation Update With 7 Day Price Move • Aug 11Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₹44.30, the stock trades at a trailing P/E ratio of 7.5x. Average trailing P/E is 13x in the Packaging industry in India. Total returns to shareholders of 158% over the past three years.
공고 • Aug 06Medi-Caps Limited, Annual General Meeting, Sep 28, 2022Medi-Caps Limited, Annual General Meeting, Sep 28, 2022, at 12:00 Indian Standard Time.
Reported Earnings • Aug 05First quarter 2023 earnings released: EPS: ₹0.52 (vs ₹2.63 in 1Q 2022)First quarter 2023 results: EPS: ₹0.52 (down from ₹2.63 in 1Q 2022). Revenue: ₹126.9m (down 27% from 1Q 2022). Net income: ₹6.32m (down 81% from 1Q 2022). Profit margin: 5.0% (down from 19% in 1Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has only increased by 39% per year, which means it is significantly lagging earnings growth.
공고 • Jul 28Medi-Caps Limited to Report Q1, 2023 Results on Aug 04, 2022Medi-Caps Limited announced that they will report Q1, 2023 results on Aug 04, 2022
Valuation Update With 7 Day Price Move • Jun 17Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₹43.20, the stock trades at a trailing P/E ratio of 5.4x. Average trailing P/E is 15x in the Packaging industry in India. Total returns to shareholders of 122% over the past three years.
Reported Earnings • May 30Full year 2022 earnings released: EPS: ₹8.05 (vs ₹9.02 in FY 2021)Full year 2022 results: EPS: ₹8.05 (down from ₹9.02 in FY 2021). Revenue: ₹698.7m (up 20% from FY 2021). Net income: ₹100.4m (down 11% from FY 2021). Profit margin: 14% (down from 19% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has only increased by 48% per year, which means it is significantly lagging earnings growth.
공고 • May 18Medi-Caps Limited to Report Q4, 2022 Results on May 25, 2022Medi-Caps Limited announced that they will report Q4, 2022 results on May 25, 2022
Valuation Update With 7 Day Price Move • Apr 06Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹57.00, the stock trades at a trailing P/E ratio of 6.5x. Average trailing P/E is 14x in the Packaging industry in India. Total returns to shareholders of 279% over the past three years.
Valuation Update With 7 Day Price Move • Feb 22Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₹50.55, the stock trades at a trailing P/E ratio of 5.8x. Average trailing P/E is 14x in the Packaging industry in India. Total returns to shareholders of 288% over the past three years.
Valuation Update With 7 Day Price Move • Feb 22Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₹50.55, the stock trades at a trailing P/E ratio of 5.8x. Average trailing P/E is 14x in the Packaging industry in India. Total returns to shareholders of 288% over the past three years.
Reported Earnings • Feb 13Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹1.67 (down from ₹2.75 in 3Q 2021). Revenue: ₹180.0m (down 1.5% from 3Q 2021). Net income: ₹20.8m (down 39% from 3Q 2021). Profit margin: 12% (down from 19% in 3Q 2021). The decrease in margin was primarily driven by higher expenses. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 68% per year whereas the company’s share price has increased by 67% per year.
공고 • Feb 03Medi-Caps Limited to Report Q3, 2022 Results on Feb 10, 2022Medi-Caps Limited announced that they will report Q3, 2022 results on Feb 10, 2022
Reported Earnings • Nov 12Second quarter 2022 earnings released: EPS ₹2.59 (vs ₹2.94 in 2Q 2021)The company reported a solid second quarter result with improved earnings and revenues, although profit margins were weaker. Second quarter 2022 results: Revenue: ₹174.4m (up 17% from 2Q 2021). Net income: ₹32.3m (up 3.3% from 2Q 2021). Profit margin: 19% (down from 21% in 2Q 2021). The decrease in margin was driven by higher expenses.
Reported Earnings • Jun 29Full year 2021 earnings released: EPS ₹11.16 (vs ₹4.69 loss in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹593.0m (up 33% from FY 2020). Net income: ₹112.4m (up ₹171.0m from FY 2020). Profit margin: 19% (up from net loss in FY 2020). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has only increased by 34% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • May 25Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹49.40, the stock trades at a trailing P/E ratio of 4.3x. Average trailing P/E is 14x in the Packaging industry in India. Total returns to shareholders of 134% over the past three years.
Valuation Update With 7 Day Price Move • Mar 06Investor sentiment improved over the past weekAfter last week's 19% share price gain to ₹35.00, the stock is trading at a trailing P/E ratio of 3x, up from the previous P/E ratio of 2.5x. This compares to an average P/E of 10x in the Packaging industry in India. Total returns to shareholders over the past three years are 51%.
Is New 90 Day High Low • Mar 05New 90-day high: ₹35.00The company is up 54% from its price of ₹22.75 on 04 December 2020. The Indian market is up 17% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Packaging industry, which is up 4.0% over the same period.
Valuation Update With 7 Day Price Move • Feb 12Investor sentiment improved over the past weekAfter last week's 42% share price gain to ₹34.80, the stock is trading at a trailing P/E ratio of 3x, up from the previous P/E ratio of 2.1x. This compares to an average P/E of 10x in the Packaging industry in India. Total returns to shareholders over the past three years are 35%.
Is New 90 Day High Low • Feb 08New 90-day high: ₹29.45The company is up 33% from its price of ₹22.10 on 10 November 2020. The Indian market is up 21% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Packaging industry, which is up 5.0% over the same period.
공고 • Feb 06Medi-Caps Limited Appoints Dharmendra Solanki as an Additional as Well as Non Executive Independent DirectorMedi-Caps Limited at its board meeting held on February 5, 2021 approved the appointment of Dharmendra Solanki as an additional as well as non executive independent Director in the company.
Reported Earnings • Feb 06Third quarter 2021 earnings released: EPS ₹3.54 (vs ₹2.63 loss in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₹182.7m (up 114% from 3Q 2020). Net income: ₹34.3m (up ₹67.5m from 3Q 2020). Profit margin: 19% (up from net loss in 3Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
공고 • Feb 01Medi-Caps Limited to Report Q3, 2021 Results on Feb 05, 2021Medi-Caps Limited announced that they will report Q3, 2021 results on Feb 05, 2021
Is New 90 Day High Low • Dec 09New 90-day high: ₹24.65The company is up 23% from its price of ₹20.05 on 10 September 2020. The Indian market is up 19% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Packaging industry, which is up 10.0% over the same period.
공고 • Nov 25Medi-Caps Limited Announces Demise of Shamsher Singh, Non-Executive Independent DirectorMedi-Caps Limited announced sudden and sad demise of Mr. Shamsher Singh, Non-Executive Independent Director of the Company, on 20 November, 2020. Mr. Shamsher Singh was on the Board of the Company since April 30, 2002 and the Company immensely benefitted from his vision and contribution during his tenure.
Is New 90 Day High Low • Nov 12New 90-day high: ₹23.95The company is up 9.0% from its price of ₹21.90 on 14 August 2020. The Indian market is also up 9.0% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Packaging industry, which is down 2.0% over the same period.
공고 • Oct 30Medi-Caps Limited to Report Q2, 2021 Results on Nov 06, 2020Medi-Caps Limited announced that they will report Q2, 2021 results on Nov 06, 2020
공고 • Jun 21Medi-Caps Limited to Report Q4, 2020 Results on Jun 26, 2020Medi-Caps Limited announced that they will report Q4, 2020 results on Jun 26, 2020